Luteal phase sertraline treatment of premenstrual dysphoric disorder (PMDD): Effects on markers of hypothalamic pituitary adrenal (HPA) axis activation and inflammation
Barone J, Ho A, Osborne L, Eisenlohr-Moul T, Morrow A, Payne J, Epperson C, Hantsoo L. Luteal phase sertraline treatment of premenstrual dysphoric disorder (PMDD): Effects on markers of hypothalamic pituitary adrenal (HPA) axis activation and inflammation. Psychoneuroendocrinology 2024, 169: 107145. PMID: 39096755, PMCID: PMC11381144, DOI: 10.1016/j.psyneuen.2024.107145.Peer-Reviewed Original ResearchPremenstrual dysphoric disorderSertraline treatmentMultilevel linear modelsDysphoric disorderHypothalamic pituitary gonadalHypothalamic pituitary adrenal (HPA) axisEffects of sertraline treatmentHypothalamic pituitary adrenal (HPA) axis activityPMDD patientsPMDD statusOpen-label sertralineMildly stressful tasksPremenstrual dysphoric disorder groupDaily symptom ratingsSevere affective symptomsEffect of groupPremenstrual symptom severityMenstrual cycle phaseAssociated with higher levelsALLO levelsInflammatory markersMenstrual cycleAffective symptomsAffective disordersClinical Interview
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply